Moderna's second quarter of 2026 demonstrates a strategic pivot towards a broader pharmaceutical portfolio, moving beyond its primary focus on COVID-19 vaccines. The company reported a total revenue of $145 million, marking a modest 2% increase compared to the previous year. This growth was primarily fueled by international collaborations and manufacturing revenues. While the company still recorded a net loss of $782 million, this represents a 5% improvement, underscoring ongoing efforts in financial discipline and operational efficiency. The executive team highlighted the expansion of its product pipeline, with promising developments in seasonal flu vaccines, combination vaccines, and oncology therapeutics, signaling a commitment to sustained growth and market diversification.
Key financial adjustments for 2026 include reduced guidance for cost of sales and research and development expenses, reflecting enhanced manufacturing efficiencies and streamlined operations. The company anticipates achieving revenue growth of up to 10% for the full year, with a projected equal split between U.S. and international markets. Significant milestones achieved during the quarter include the positive recommendation for its seasonal flu vaccine, mFLUSIVA, from the U.S. VRBPAC, and an agreement with the European Commission for up to 24 million doses of mRESVIA, its RSV vaccine. Moderna's leadership also stressed the importance of late-stage data readouts in areas such as adjuvant melanoma and rare diseases, which are crucial to its long-term growth strategy and aim to solidify its position as a leader in mRNA technology.
Expanding Vaccine Portfolio and Global Market Reach
Moderna's latest earnings call highlighted significant progress in diversifying its vaccine portfolio and expanding its global footprint. The company's seasonal flu vaccine, mFLUSIVA (mRNA-1010), is on track for potential approval, with a positive recommendation from the U.S. VRBPAC and an August 5, 2026 PDUFA date. This marks a crucial step towards making the vaccine available to patients and broadening Moderna's commercial offerings beyond COVID-19. Furthermore, the company secured a joint procurement contract with the European Commission for up to 24 million doses of mRESVIA, its respiratory syncytial virus (RSV) vaccine, across six European countries. This agreement, alongside mNEXSPIKE approvals in Japan and Taiwan and label expansions in Australia and Mexico, illustrates Moderna's aggressive push into new international markets and strategic partnerships to drive revenue growth.
In addition to these achievements, Moderna is actively updating its COVID-19 vaccines, Spikevax and mNEXSPIKE, to target the XFG strain for the upcoming vaccination season, demonstrating its adaptability to evolving health challenges. Real-world evidence for mNEXSPIKE has shown promising effectiveness against COVID-related hospitalization, especially among older adults, with approximately 59% efficacy in those aged 65 and older. The company is also making strides with its combination flu and COVID vaccine, mCOMBRIAX, which has received approval in the European Union and is under review in other key markets. Despite a setback with the norovirus vaccine (mRNA-1403) requiring an additional cohort for its Phase III trial, Moderna's overall strategy focuses on leveraging its mRNA platform to address a wider range of infectious diseases, reinforcing its commitment to global health security and expanding its presence in diverse geographical regions.
Oncology and Rare Disease Pipeline Advancements
Moderna's commitment to innovation extends significantly into its oncology and rare disease pipelines, showcasing a robust array of clinical programs designed to address unmet medical needs. A focal point is Intismeran, an individualized neoantigen therapy developed in collaboration with Merck, which is undergoing multiple Phase II and Phase III studies across various cancer types. The Phase III study in adjuvant melanoma is fully enrolled, with an interim analysis anticipated in 2026, building on positive 5-year Phase II data that demonstrated sustained clinical benefits and the induction of neoantigen-specific T cells. This program underscores the potential of personalized cancer immunotherapy, with ongoing trials in non-small cell lung cancer, renal cell carcinoma, and muscle invasive bladder cancer, illustrating a comprehensive approach to evaluating this therapy's efficacy across different tumor stages.
Beyond Intismeran, Moderna is advancing several other promising oncology candidates, including mRNA-4359 for metastatic melanoma and non-small cell lung cancer, and two additional cancer antigen therapies, mRNA-4106 and mRNA-4200, for advanced solid tumors, with dosing for mRNA-4200 having recently commenced. The company is also exploring cancer interception with mRNA-4194 in Lynch syndrome and progressing with its T-cell engager, mRNA-2808, for multiple myeloma. In the realm of rare diseases, the registrational study for propionic acidemia (PA) with mRNA-3927 is fully enrolled, with data expected in 2026, offering hope for patients with this severe metabolic disorder. These diverse programs collectively highlight Moderna's strategic vision to harness mRNA technology for a broad spectrum of therapeutic applications, aiming to deliver transformative medicines and expand its market reach in specialized treatment areas.